Vulcan leads $10.5m Series A for Singapore's Amili

Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Seeds Capital, Pureland Group, Blue7, and GK Goh also participated. The company said the roster was chosen for its expertise across biotechnology, healthcare, and food technology.

Amili describes itself as the largest precision gut microbiome company in Southeast Asia. Its core operations include the development of diagnostics tests, predictive algorithms and microbiome-modifying interventions. It is also establishing a multi-ethnic Asia-centric microbiome repository of data and samples, including Southeast Asia’s only microbiome bank.

The company has initiated more than 20 research studies since its inception in 2014. These focus on a range of healthcare topics, including faecal microbiota transplants, an area where Amili claims to be the only collection, analysis, and processing provider in Southeast Asia. It also owns Bio & Me, a direct-to-consumer (D2C) precision gut health brand that is planning a regional rollout.

“Although gut health research has advanced steadily over the years in other regions, there is still a big gap in research that is representative of the Asian population. We are excited to journey with Amili as it advances microbiome research and positively impacts millions of lives,” Tommy Teo, a managing director of Vulcan, said in a statement.

Teo, a former executive director at Northstar Group, set up Vulcan’s Asia headquarters in Singapore in 2019. The firm invests as a family office with an evergreen pool of capital and a single LP, Vulcan Inc. The Asia program was initially established with USD 100m and a remit to write cheques of USD 1m to USD 10m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Southeast Asia
• Healthcare
• Technology
• Early-stage
• Singapore
• Vulcan Capital
• TVM Capital Healthcare